Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

NANOMED2020 intends to bring more Nanomedicine products to European patients

16.10.2012
VDI/VDE-IT announced on 10th October a collaboration with key European Nanomedicine players which is funded by the European Commission.
This strong partnership of relevant stakeholders aims at identifying key areas for Nanomedicine research and at establishing novel concepts for translation of nanomedical innovations into clinical practice. The project called “NANOMED2020” started on 1st September 2012 and has duration of 18 months.

Making Europe a center for Nanomedicine research, development and translation is the goal of this project. To achieve this goal the proposed project unites partners already representing the largest network of active stakeholders in the Nanomedicine area as of today in Europe, embracing roughly 200 hundred Universities, Research Institutes, Hospitals and Public Health Institutions, Small and Medium-sized Enterprises (SMEs) and Small and Large Industry organizations.

What are the needs and the problems? Excellent academic research groups may need to better understand the market and the medical needs. There are a large number of pharmaceutical and medtech companies that have a comprehensive and direct access to market but these companies struggle to handle radical innovation. At the same time there is a small number of SMEs trying to add new innovation onto the market, but these few companies are too small to exploit the large potential of Nanomedicine. A consolidated pan-European approach to structure this field is therefore highly needed to bring Nanomedicine products more efficiently to patients.

“We are proud that we were able to receive funding for this project from the European Commission” said Dr. Sebastian Lange, the coordinator of this project at VDI/VDE-IT. “Seven renowned Nanomedicine players from six European countries hope to build a pertinent European Nanomedicine community involving all key players. We aim to define the resources, gaps and needs for development and implementation of Nanomedicine research into marketable innovations to be used by doctors for the benefit of patients.”

The NANOMED2020 project is an opportunity for all stakeholders from industry, academia, clinic and public authorities to provide the European Commission with input for a future Nanomedicine topic within Horizon 2020. This will make Nanomedicine an important contributor to the future European healthcare system with a beneficial impact on improved treatment for patients and on social challenges such as ageing population.

ABOUT NANOMED2020
The NANOMED2020 Support Action project, funded with a contribution of 500 000€ by the European Commission under the Work Programme FP7-HEALTH-2012 (Area 2012.4.1-5: Preparing the future for health research and innovation) was launched on 1st September 2012 and is planned to have duration of 18 months.
Partners of the NANOMED2020 project:

• ETP Nanomedicine c/o VDI/VDE-IT (Coordinator), http://www.etp-nanomedicine.eu
• CLINAM Foundation, http://www.clinam.org
• Instituto de Salud Carlos III, http://www.isciii.es
• Bioanalytik Muenster e.V., http://www.bioanalytik-muenster.de
• Nanobiotix, http://www.nanobiotix.com
• Fondazione Don Carlo Gnocchi ONLUS, http://www.dongnocchi.it
• SINTEF, http://www.sintef.no

For more information about the project consult: http://www.etp-nanomedicine.eu/public/news-events/news/start-of-nanomed-2020

The website www.nanomed2020.eu will be launched soon. Latest news on Nanomedicine research, strategic challenges and innovation concepts will be available there.

ABOUT Nanomedicine
Nanomedicine is understood to be the enabling instrument for personalized, targeted and regenerative medicine by delivering the next level of new drugs, treatments and implantable devices to clinicians and patients. Beyond that, Nanomedicine provides important new tools to deal with the grand challenge of an ageing population and is thought to be instrumental for improved and cost effective health-care, one crucial factor for making medicines and treatments available and affordable to all.

ABOUT ETP Nanomedicine c/o VDI/VDE-IT, http://www.etp-nanomedicine.eu, http://www.vdivde-it.de
VDI/VDE-IT is a leading service provider in the field of innovation and technology for customers in Germany and all over the world. We analyse, support and organise innovation and technology for clients with political, research, industry and finance backgrounds.

Since 2008, VDI/VDE-IT is managing the Office of the European Technology Platform on Nanomedicine, ETPN. This platform was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies such as Philips, Siemens and UCB, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for Nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative Nanomedicines. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the EC and the European Member States.

Press contact

NANOMED2020 Coordinator
Dr. Sebastian Lange
secretariat@etp-nanomedicine.eu
+49 30 310078 155

Wiebke Ehret | idw
Further information:
http://www.etp-nanomedicine.eu

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Osaka university researchers make the slipperiest surfaces adhesive

18.10.2017 | Materials Sciences

Space radiation won't stop NASA's human exploration

18.10.2017 | Physics and Astronomy

Los Alamos researchers and supercomputers help interpret the latest LIGO findings

18.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>